Moderna's (MRNA) - Get Report CEO Stephane Bancel said the U.S. government could authorize emergency use of the company's experimental Covid-19 vaccine in December if Moderna gets positive interim results in November from a large clinical trial, The Wall Street Journal reported.
Bancel, speaking Monday at a Journal tech conference, said, however, that if sufficient interim results from the trial take longer to get, government approval of the vaccine may not occur until early next year.
Moderna has been a front-runner, along with Pfizer and its partner BioNTech, in the race to develop a Covid-19 vaccine.
Pfizer said last week it could apply for emergency use approval of its developing coronavirus vaccine treatment as early as November if data from ongoing trials show it's safe and effective.
In the past year, Moderna shares are up 355%.
Jim Cramer discusses whether or not Moderna's December timeline is realistic and how the company is not a household name.
"As much as they've got the code and they started early...they may be ready, but I don't know how many people will take it," Cramer said.
Watch more in the video above.
Latest Videos From TheStreet and Jim Cramer:
- Jim Cramer Says Bank Stocks Aren't Worth Buying
- Coronavirus: The Latest Numbers on the COVID-19 Pandemic
- Apple iPhone 12 Lineup Gets Positive Wall Street Reviews
- Why Have U.S. Stocks Recovered Much Faster Than European Stocks Have?
- Dodgers Head to the World Series: Top Stories, Sports and Business News — Oct. 19
- DraftKings Falls as Lockup for Secondary Offering Expires
- Jim Cramer Says Earnings Pinpoint Stocks to Buy With or Without Stimulus